Compare Slide Insurance Holdings Inc. Common Stock (SLDE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Slide Insurance Holdings Inc. Common Stock vs GeneDx Holdings Corp — how do they compare? Slide Insurance Holdings Inc. Common Stock trades at $25.59 (market cap $2.98B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: Slide Insurance Holdings Inc. Common Stock is the larger of the two by market cap, and Slide Insurance Holdings Inc. Common Stock pays a 1.1% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Slide Insurance Holdings Inc. Common Stock for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| SLDE | WGS | |
|---|---|---|
Market Cap | $2.98B | $1.94B |
Volume | 927,183 | 524,385 |
Sector | Financials | Health |
52-Week High | $26.48 | $167.51 |
52-Week Low | $14.38 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $1.78B | $1.97B |
Dividend Yield | 1.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLDE trades at $25.50, down slightly (-0.12%) on the day, with strong fundamental metrics including a P/E of 6.16 and net income margin of 40.02%. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results scheduled for October 27, 2026. Revenue growth from $1.16B in 2025 to projected $1.4B in 2026 demonstrates solid business momentum, supported by expanded insurance offerings in key markets.
The stock presents attractive value with strong profitability and analyst support (80% buy ratings), though hurricane exposure in Florida remains a key risk. Current price sits near consensus target of $25.00, suggesting limited near-term upside but solid fundamentals for long-term investors. Management's share repurchase program and dividend initiation provide additional shareholder value support.
GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.
The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Slide Insurance Holdings Inc. Common Stock
Slide Insurance Holdings, Inc. is a technology-enabled insurance company based in Florida that underwrites coastal specialty personal lines insurance, including homeowners and condominium unit owner policies, and also provides reinsurance and insurance agency services.
Read more on SLDE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
